BRIM Biotechnology, Inc. utilizes integrated and efficient translational science to develop novel treatments to combat and cure diseases. With our extensive experience and successful track record of translating discovery research to the clinic, we are able to identify and nurture promising drug candidates through our unique drug development engine to deliver clinical assets that are ready for partnership. Our main pipeline and platform are as follows:

BRM421

● First-in-class treatment for Dry Eye Disease
● Safe and effective therapy with fast relief
● The first patient was treated in February, and we expect to obtain the results of a Phase 3 trial by the end of 2023.

BRM424

● Orphan drug for Neurotrophic Keratitis
● Phase 2 ready

PDSP technology platform (Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide, PDSP)

● Repairs damaged tissues by promoting stem cell proliferation and differentiation
● Early-onset potential in various disease animal models
● Low immunogenicity, no endotoxin risk, and high pharmaceutical stability